Related posts

Friday rally cap choppy weakU.S inflation hot, GDP cool, Wall Street down, TSX flatMicrosoft hits highs, markets rise
Investor Insights

This summary was created by AI, based on 11 opinions in the last 12 months.

Experts have mixed opinions on Bristol Myers Squibb (BMY-N). Some are optimistic about the company's AI potential and strong dividend, while others express concerns about patent cliffs and the need for a turnaround. The company's recent acquisitions and partnerships in the pharmaceutical industry are seen as positive moves to address challenges. Despite differing views on the stock's performance, there is a consensus that it holds potential but also faces significant hurdles in the coming years.

Consensus
Mixed
Valuation
Fair Value
BUY
Their Cobenfy drug got FDA approval

BMY paid nearly $13 billion to buy the company that was developing Cobenfy. This could could help BMY get the patent cliffs of their other drugs in a few years.

biotechnology / pharmaceutical
WATCH

Credit them for being a company which led to the schizophrenia drug, which the FDA just approved. BMY has been unloved, selling before 8x PE at a 4% dividend. Puzzling, but shares will certainly rise. He sold it last year and may re-enter it.

biotechnology / pharmaceutical
BUY

Pays over a 5% dividend. Was the top pharma, but slipped. Their purchase of Celgene disappointed while revenue growth has been negative. Earnings shrunk last year. But he likes the new CEO and him buying 3 companies in onocology and neuroscience, both growth areas. Also, there have been cost cuts. Be patient though. They reported a clean top and bottom line beat last week and issued very strong guidance. Trades at a cheap 7x 2025 PE.

biotechnology / pharmaceutical
BUY

It just raised its forecast, released better numbers than expected and revealed a slew of new, promising drugs. Shares have jumped. The new CEO knocked out of the park the latest numbers, instead of missing numbers as so often before.

biotechnology / pharmaceutical
WEAK BUY

They just reported a Q2 beat. It hasn't performed well, but is finally rebounding a little. Their product pipeline will be good for the next few years.

biotechnology / pharmaceutical
DON'T BUY

His whole mantra is to buy good companies that are getting better. He wants to have a strong fundamental view, and he wants the market to show that it's agreeing with him -- he doesn't want to be alone in the woods in a good market, not participating.

Problem is a fair bit of debt, low growth. In a market like this, you only need 20 companies to get a broadly diversified portfolio. Don't need to take on the risk of this one. Avoid.

biotechnology / pharmaceutical
DON'T BUY

It will need a lot of time to turn around. It hit bottom when it touched a 5.75% dividend yield. You won't see good news here until 2029 or 2030.

biotechnology / pharmaceutical
SELL

Dow 7% in May. Lots of struggle in the healthcare space. Will sell.

biotechnology / pharmaceutical
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Dec 12/23, Down 13%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with BMY has triggered its stop at $44.  To remain disciplined, we recommend covering the position at this time.  

biotechnology / pharmaceutical
DON'T BUY
A good AI play in pharma?

The market lacks patience for them to get into AI, though he disagrees and the dividend is good.

biotechnology / pharmaceutical
WEAK BUY

A lot of their big drugs are coming off patent, and they will need 5 years to turn around. Meanwhile, collect the 5% dividend as you wait. Be patient. He prefers Eli Lilly.

biotechnology / pharmaceutical
WAIT

Down 23% in the past 6 months. Pays a 5% dividend. Be patient and give the current CEO a chance to turn things around.

biotechnology / pharmaceutical
TOP PICK

Big on immune oncology and cardio. Technically doesn't look great, but eventually "the train will come along and collect the mail bag". Makes a ton of $$ in NA. Wide moat. Concerns about pipeline, but he thinks it's pretty good. Limited downside. Yield is 4.9%.

Good pricing power. Because products are so specialized, FDA puts them on sort of a fast track.

(Analysts’ price target is $59.92)
biotechnology / pharmaceutical
COMMENT

In the past quarter, They recently bought 3 companies, including Mirati, a small oncology company, and Karuna who may develop a wonder drug to treat schizophrenia. BMY needs to buy companies, because their top 3 drugs face steep patent cliffs, like a blood-clot drug, accounting for over 61% of 2023 (Jan-Sept)'s sales.

biotechnology / pharmaceutical
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly

The company has partnered with a Chinese pharma company for a new drug to lung and breast cancer patients.  They will have exclusive rights outside of China. It trades at 13x earnings and supports a ROE of 26%.  It has a good dividend, backed by a payout ratio under 60% of cash flow.  The company has been prudentially using some cash reserves to aggressively buy back shares and retire debt.  We recommend placing a stop at $44, looking to achieve $63 -- upside potential of 23%.  Yield 4.4% 

(Analysts’ price target is $62.82)
biotechnology / pharmaceutical
Showing 1 to 15 of 202 entries

Bristol Myers Squibb(BMY-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 7

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 5

Total Signals / Votes : 12

Stockchase rating for Bristol Myers Squibb is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Bristol Myers Squibb(BMY-N) Frequently Asked Questions

What is Bristol Myers Squibb stock symbol?

Bristol Myers Squibb is a American stock, trading under the symbol BMY-N on the New York Stock Exchange (BMY). It is usually referred to as NYSE:BMY or BMY-N

Is Bristol Myers Squibb a buy or a sell?

In the last year, 12 stock analysts published opinions about BMY-N. 7 analysts recommended to BUY the stock. 5 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Bristol Myers Squibb.

Is Bristol Myers Squibb a good investment or a top pick?

Bristol Myers Squibb was recommended as a Top Pick by on . Read the latest stock experts ratings for Bristol Myers Squibb.

Why is Bristol Myers Squibb stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Bristol Myers Squibb worth watching?

12 stock analysts on Stockchase covered Bristol Myers Squibb In the last year. It is a trending stock that is worth watching.

What is Bristol Myers Squibb stock price?

On 2024-10-03, Bristol Myers Squibb (BMY-N) stock closed at a price of $54.2.